Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
 
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve
Pubget Overpricing |  
lüll
TSH suppressive therapy: an overview of long-term clinical consequences Cooper DSHormones (Athens) 2010[Jan]; 9 (1): 57-9An overview of long-term clinical consequences of TSH suppressive therapy provides evidence that serum TSH levels should be maintained at levels <0.1 mU/l in high-risk (stage III and IV) patients, whereas lower-risk patients should be allowed to have their TSH levels rise into the normal range after residual disease has been ruled out by imaging and/or stimulated thyroglobulin measurement. The proper management of patients with known residual thyroid cancer, who are also elderly or who have underlying serious comorbidities (e.g., osteoporosis, cardiovascular disease, diabetes), is uncertain and requires a high degree of clinical experience and judgment.|Humans[MESH]|Neoplasm Recurrence, Local/prevention & control[MESH]|Neoplasm Staging[MESH]|Neoplasm, Residual[MESH]|Practice Guidelines as Topic[MESH]|Risk Factors[MESH]|Thyroglobulin/blood[MESH]|Thyroid Neoplasms/complications/*drug therapy[MESH]|Thyroid Nodule/complications/*drug therapy[MESH]|Thyrotropin/*blood[MESH]|Thyroxine/*adverse effects/*therapeutic use[MESH]|Treatment Outcome[MESH] |
